Identification of low-dose ligand dependent drug-resistance in ALK/ROS1 positive NSCLC via CRISPR library screening

被引：0
|
作者：
Kondo, Nobuyuki
Utsumi, Takahiro
Uchibori, Ken
Miyazaki, Yasunari
Katayama, Ryohei
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-5839
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5839
引用
收藏
页数：2
相关论文
共 4 条
  • [1] Detection of low-dose ligand dependent drug-resistance through loss of tumor suppressor genes in ALK/ROS1 positive NSCLC
    Kondo, Nobuyuki
    Miyazaki, Yasunari
    Katayama, Ryohei
    Nishio, Makoto
    Uchibori, Ken
    CANCER SCIENCE, 2024, 115 : 114 - 114
  • [2] MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF
    Kondo, Nobuyuki
    Utsumi, Takahiro
    Shimizu, Yuki
    Takemoto, Ai
    Oh-hara, Tomoko
    Uchibori, Ken
    Subat-Motoshi, Sophia
    Ninomiya, Hironori
    Takeuchi, Kengo
    Nishio, Makoto
    Miyazaki, Yasunari
    Katayama, Ryohei
    JCI INSIGHT, 2023, 8 (24)
  • [3] A phase I, dose-escalation and expansion study of TQ-B3139, a novel ALK TKI, in Chinese ALK or ROS1 positive advanced non-small cell lung cancer (NSCLC).
    Ma, Yuxiang
    Yang, Nong
    Li, Su
    Zhao, Hongyun
    Li, Liu
    Yang, Haiyan
    Fang, Wenfeng
    Zhang, Yang
    Hong, Shaodong
    Xiong, Yi
    Zhou, Chunhua
    Zhang, Yongchang
    Zeng, Liang
    Zhang, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Afatinib reverses ceritinib resistance (CR) in ALK/ROS1-positive non-small-cell lung cancer cell (NSCLC) via suppression of NRG1 pathway
    Chen, Hui
    Zhang, Qiang
    Zhang, Yu
    Jia, Bin
    Zhang, Bin
    Wang, Changli
    ONCOTARGETS AND THERAPY, 2018, 11 : 8201 - 8209
1